Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

AZD2014, mTOR Inhibitor

AZD2014, mTOR Inhibitor

$169.00
A highly potent, selective and ATP-competitive mTOR inhibitor with a high level of selectivity against other members of the PIKK family.
Catalog No. Unit Price Qty
M60090-5s 5 mg solid $169.00
M60090-50s 50 mg solid $960.00

Details

Product Information
Chemical Name: 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide
Molecular Weight: 462.54
Formula: C25H30N6O3
Purity: ≥ 98%
CAS#: 1009298-59-2
Solubility: DMSO up to 100 mM
Storage: Powder: 4oC 1 year DMSO: 4oC 3 month -20oC 1 year


Biological Activity:

AZD2014 is a highly potent, selective and ATP-competitive mTOR inhibitor (IC50 = 2.8 nM). It displays a high level of selectivity against other members of the PIKK family (IC50 against PI3K isoforms α, β, γ, δ = 3.8 µM, >30 µM, >30 µM and >29 µM, respectively) and is inactive against a general panel of over 200 kinases when tested at 10 µM. AZD2014 inhibits both mTORC1 and mTORC2 in vitro (pS6 (S235/236 ) IC50 = 0.2 µM, pAKT (S473) IC50 = 0.08 µM) and has shown dose-dependent tumor growth inhibition in a mouse MCF7 xenograft model alongside modulation of mTORC1 and mTORC2 biomarkers. Different from AZD8055, AZD2014 shows consistent exposure in rodents and a low turnover in human hepatocyte incubations. It is in phase I clinical development for advanced solid malignancies.


How to Use:

In vitro: AZD2014 was used at 2.5-5 µM concentration in vitro and cellular assays.

In vivo: AZD2014 was orally dosed to mice at 2.5-20 mg/kg once or twice per day to inhibit tumor growth.


Reference:

  1. 1.  Guichard SM, at al. AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer. (2012) AACR Annual Meeting: Chicago, Abstract 917.
  2. 2.  Pike KG, et al. Optimization of potent and  selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014. (2013) Bioorg Med Chem Lett. In press.


AZD2014_spec.pdf



Products are for research use only. Not for human use.

Description

Details

Product Information
Chemical Name: 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide
Molecular Weight: 462.54
Formula: C25H30N6O3
Purity: ≥ 98%
CAS#: 1009298-59-2
Solubility: DMSO up to 100 mM
Storage: Powder: 4oC 1 year DMSO: 4oC 3 month -20oC 1 year


Biological Activity:

AZD2014 is a highly potent, selective and ATP-competitive mTOR inhibitor (IC50 = 2.8 nM). It displays a high level of selectivity against other members of the PIKK family (IC50 against PI3K isoforms α, β, γ, δ = 3.8 µM, >30 µM, >30 µM and >29 µM, respectively) and is inactive against a general panel of over 200 kinases when tested at 10 µM. AZD2014 inhibits both mTORC1 and mTORC2 in vitro (pS6 (S235/236 ) IC50 = 0.2 µM, pAKT (S473) IC50 = 0.08 µM) and has shown dose-dependent tumor growth inhibition in a mouse MCF7 xenograft model alongside modulation of mTORC1 and mTORC2 biomarkers. Different from AZD8055, AZD2014 shows consistent exposure in rodents and a low turnover in human hepatocyte incubations. It is in phase I clinical development for advanced solid malignancies.


How to Use:

In vitro: AZD2014 was used at 2.5-5 µM concentration in vitro and cellular assays.

In vivo: AZD2014 was orally dosed to mice at 2.5-20 mg/kg once or twice per day to inhibit tumor growth.


Reference:

  1. 1.  Guichard SM, at al. AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer. (2012) AACR Annual Meeting: Chicago, Abstract 917.
  2. 2.  Pike KG, et al. Optimization of potent and  selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014. (2013) Bioorg Med Chem Lett. In press.


AZD2014_spec.pdf



Products are for research use only. Not for human use.

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: